Advanced searches left 3/3

Cardiorenal Syndrome - DOAJ

Summarized by Plex Scholar
Last Updated: 10 January 2023

* If you want to update the article please login/register

Diagnostic dilemma: Cardiorenal syndrome as an unusual presentation of IgG4-related disease

The patient was dialysis dependent for about 45 days after kidney biopsy revealed signs of acute tubulointerstitial nephritis with IgG4-positive plasma cells and no glomerular involvement. Both renal and cardiac functions responded to steroids therapy, resulting in significant improvements in both renal and cardiac functions. This case demonstrates the clinical significance of IgG4 RKD as a key difference in patients with ATIN presenting as a medical disorder.

Source link: https://doi.org/10.4103/ijn.ijn_143_21


The molecular mechanisms and intervention strategies of mitophagy in cardiorenal syndrome

Cardiorenal syndrome is a disorder of the heart and kidney in which acute or chronic injury of one organ can lead to acute or chronic dysfunction of the other. The involvement of mitophagy in CRS progression is shown by emerging evidence, including cardiovascular disease and chronic kidney disease. Mitophagy dysfunction has been linked to a vicious loop between CKD and CVD, which ultimately accelerates CRS progression. Recent reports also revealed that targeting mitophagy may be a promising therapeutic strategy for CRS, including medical products, stem cells, and small molecule agents.

Source link: https://doi.org/10.3389/fphys.2022.1008517


Exploring New Kingdoms: The Role of Extracellular Vesicles in Oxi-Inflamm-Aging Related to Cardiorenal Syndrome

In recent years, the incidence of age-related chronic diseases has increased. In this report, we intend to explore the role of extracellular vesicles in human cardiorenal syndrome development and their potential as biomarkers, targets, or vehicles of drugs to treat this disorder.

Source link: https://doi.org/10.3390/antiox11010078


Cardiorenal Syndrome: Emerging Role of Medical Imaging for Clinical Diagnosis and Management

The interconnection between heart and kidneys is causing heart and kidney dysfunction, which can lead to abnormalities in the other. The key clinical issues that are associated with cardiorenal syndrome are the lack of diagnostic instruments for early diagnosis, prognosis, and evaluation of therapeutic effects. This report details the applicability of each imaging technique in the evaluation of CRS, as well as the future technological potential of each imaging technique.

Source link: https://doi.org/10.3390/jpm11080734


Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens—From a Cardiologist’s View

The reciprocal relationship between cardiac and renal injury is closely intertwined in cardiorenal syndrome, heart disease, and renal failure. Type 1 CRS is the most common and is most related to acute heart failure. Pre-existing chronic kidney disease is common and contributes to acute kidney injury in CRS type 1 patients. Patients with chronic heart disease, acute and chronic kidney disease, and systemic illnesses that affect both the heart and kidney are among the remaining CRS types. For CRS, comprehensive u201call-in-one (u201d) magnetic resonance imaging methods, including cardiac magnetic resonance imaging as well as functional MRI of the kidneys and brain MRI are among the suggested for CRS. Devices involved in the improvement of myocardial function have also demonstrated positive effects on renal function.

Source link: https://doi.org/10.3390/jcm11237041


The Effect in Renal Function and Vascular Decongestion in Type 1 Cardiorenal Syndrome Treated with Two Strategies of Diuretics, a Pilot Randomized Trial

Abstract Aim 1. 0 Aim of type 1 coronary syndrome The main treatment method for type 1 cardiorenal syndrome is vascular decongestion. It is likely that sequential blockage of the renal tubule with combined diuretics will result in similar outcomes as stepped-dose furosemide. Methods In a 1:1 manner, a pilot double-blind placebo controlled trial of CRS1 patients was allocated in a 1:1 fashion to SF or CD. During the first day, the SF group received a steady infusion of furosemide 100 mg, with daily incremental doses increasing to 200 mg, 300 mg, and 400 mg. Conclusion In patients with CRS1 and a high risk of diuretics, the use of CD in comparison to SF has the same results in renal recovery, diuresis, arterial decongestion, and adverse events as well as adverse events, and it can be considered a natural alternative therapy.

Source link: https://doi.org/10.1186/s12882-021-02637-y


Predialysis serum lactate levels could predict dialysis withdrawal in Type 1 cardiorenal syndrome patients

A summary: Renal replacement therapy is a safe and effective rescue therapy for Type 1 cardiorenal syndrome. According to previous studies, type 1 CRS patients with severe renal impairment were susceptible to sepsis, and serum lactate was correlated with the risk of mortality in patients with sepsis. However, the correlation between serum lactate level and type 1 CRS patients requiring RRT is uncertain. Methods: An inception cohort of 500 type 1 CRS patients who received RRT in a tertiary-care referral hospital in Taiwan from August 2011 to January 2018 were recruited. In addition, the correlations between hyperlactatemia and dialysis dependence were consistent in patients with and without sepsis. Interpretation: The serum lactate level is reliable and capable of forecasting the prognosis as well as the qSOFA severity for clinical decision-making for treating type 1 CRS patients.

Source link: https://doi.org/10.1016/j.eclinm.2021.101232


Grb2 Induces Cardiorenal Syndrome Type 3: Roles of IL-6, Cardiomyocyte Bioenergetics, and Akt/mTOR Pathway

Following acute kidney disease, Cardiorenal syndrome type 3 is causing heart disease. Although many experiments have found that cardiovascular, oxidative stress, and cardiomyocyte death are all involved in cardiac pathophysiological changes during CRS-3, there is no such study to determine the primary mediator of cardiac dysfunction. A Molecular analysis revealed that augmented Grb2 caused cardiomyocyte mitochondrial metabolism disorder by blocking the Akt/mTOR signaling pathway. Besides, Mouse Inflammation Array Q1 confirmed IL-6 as the upstream regulator of Grb2 upregulation after AKI.

Source link: https://doi.org/10.3389/fcell.2021.630412


Heart failure and cardiorenal syndrome: a case report

Cardio-Renal Syndrome is a renal abnormality that occurs in a significant proportion of pts hospitalized for congestive heart failure in a large proportion. Because of the improved survival of HF patients, the incidence of CRS has likely increased. Admissions data can be used to identify patients at a high risk of getting WRF. a 70-year-old diabetic man with post-ischemic cardiomyopathy and chronic kidney disease alerted to our division for acute heart failure. When traditional medical therapies fail and/or patients become allergic to diuretics, Ultrafiltration is now restricted to patients with volume overload, and/or patients become allergic to diuretics.

Source link: https://doi.org/10.7175/cmi.v5i1.511


Klotho relieves inflammation and exerts a cardioprotective effect during renal ischemia/reperfusion-induced cardiorenal syndrome

Background: The most common cause of acute kidney injury is revascular ischemia and reperfusion injury. This research sought to investigate Klotho's therapeutic role in CRS after unilateral renal IRI by its anti-inflammatory response. Methods: We investigated renal tissue structure and function, intracellular Ca2+ metabolism, intracellular Ca2+ dynamics, and serum cytokine levels from C57BL/6 mice with unilateral renal IRI by occluding the left pedicle for 60 min and reperfusion for eight days. The left renal tissue was damaged after Klotho treatment for eight days, but renal function was restored thanks to correct kidney tissue preservation. As Ca2+ transient decay, an increase in spontaneous Ca2+ release, and the occurrence of pro-arrhythmic events, as well as a decrease in systolic Ca2+ transient decay, a decrease in systolic Ca2+ transient decay, and low cell contraction were all reduced, as well as a decrease in systolic Ca2+ transient decay, an increase in spontaneous Ca2+ release and the occurrence of pro-arrhythmic.

Source link: https://doi.org/10.1016/j.biopha.2022.113515

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions